Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 2770Carcinoma, Non-Small-Cell Lung 2267Prostatic Neoplasms 1430Colorectal Neoplasms 1296Neoplasms 1262Multiple Myeloma 1086Lung Neoplasms 1050Neoplasm Metastasis 996Leukemia, Myeloid, Acute 985Lymphoma 900Melanoma 864Pancreatic Neoplasms 820Ovarian Neoplasms 808Carcinoma, Hepatocellular 783Stomach Neoplasms 754Recurrence 752Leukemia 733Lymphoma, Non-Hodgkin 685Leukemia, Lymphocytic, Chronic, B-Cell 665Squamous Cell Carcinoma of Head and Neck 618Lymphoma, Large B-Cell, Diffuse 617Precursor Cell Lymphoblastic Leukemia-Lymphoma 605Head and Neck Neoplasms 601Brain Neoplasms 593Carcinoma, Renal Cell 587Glioblastoma 573Rectal Neoplasms 565Sarcoma 523Myelodysplastic Syndromes 522Lymphoma, Follicular 516

Interventions

Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hematopoietic System--Cancer × Clear all
NCT03654703 2018-08-31

Improved Post-Transplant Cyclophosphamide Regimens for Pediatric Patients With Refractory AML

Capital Research Institute of Pediatrics

Phase 2 Unknown
100 enrolled

Hematopoietic System--Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡